BLTE BELITE BIO INC

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 17, 2025, is available through its website (). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on ,,,or visit us at .

Media and Investor Relations Contact:

Jennifer Wu

Julie Fallon



EN
17/03/2025

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in the Leerink Global Healthcare Conference

Belite Bio to Participate in the Leerink Global Healthcare Conference SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- , Inc  (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET. Webcast Link InstructionsA webcast of each presentation can be accessed under the "Events" tab on the inv...

9m 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year...

Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q2 2026Completed enrollment in the Phase 2/3 DRAGON II trial in STGD1Completed a $402 million underwritten public offering of American Depositary SharesConference call and webcast on Monday, March 2, 2026, at...

2h / 9m 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, U...

Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2025. ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Participation at the 41st Asia-Pacific Academy of...

Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in the upcoming Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress, taking place February 5-7, 2026 in Hong Kong. The presentations will include previously disclosed topli...

January 29, 2026 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tin...

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1) Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p-value=0.0033)60 adolescent STGD1 subjects enrolled in DRAGON II clinical trial across Japan, the United States, and the United KingdomBelite Bio plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in 1H 2026 SAN DIEGO, Jan. 27, 2...

January 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch